Retatrutide pharmacokinetics: what is the half-life?

What is retatrutide's half-life?

The reported half-life of retatrutide — the time it takes for the amount in the blood to fall by half — is approximately six days (Coskun et al., Cell Metabolism, 2022; restated in Urva et al., The Lancet, 2022). Across the six dose levels of the single-dose trial, geometric-mean half-lives ran from 134 to 165 hours, about 5.6 to 6.9 days, so six days is a summary of that band rather than one measured value (Coskun et al., Cell Metabolism, 2022). The paper describes that half-life as supporting a once-weekly dosing regimen in the trials. The retatrutide research guide covers what the compound is; this page covers what the body does to it.

A half-life is a clock, not a wall. After one half-life, about half of the measured amount remains in circulation; after two, about a quarter. A six-day clock means the concentration of retatrutide falls by half roughly once a week, which is why the figure sits at the centre of every conversation about the compound.

The summary hides real spread. In the single-dose trial, the individual half-lives behind those means ran from 104 to 225 hours — the minimum and maximum in the trial's t½ column, a wider span than the 134-to-165-hour band of geometric means (Coskun et al., Cell Metabolism, 2022). A later review restates the same summary — dose-proportional pharmacokinetics with a half-life of approximately six days — as a description of the earlier work, not as a new measurement (Jastreboff et al., New England Journal of Medicine, 2023).

Evidence limits

What has not been published about retatrutide's pharmacokinetics?

The gaps continue downstream. No Phase 3 pharmacokinetic tables had been published as of 2026. No trial has compared retatrutide's pharmacokinetics head-to-head against semaglutide or tirzepatide in one study — how retatrutide, Mounjaro, and Ozempic differ is a comparison of separate published records, not of one shared measurement. No published accumulation ratio or time-to-steady-state figure exists either: the multiple-dose paper's full pharmacokinetic table was not retrievable for this record, so the honest statement is that the number is not available.

The people behind the numbers matter as much as the numbers. The single-dose trial dosed 45 healthy adults in Singapore, of whom 42 were male and 44 were Asian (Coskun et al., Cell Metabolism, 2022) — a real generalisation limit, named rather than buried. And the weight and blood-sugar changes reported in these same papers are pharmacodynamic outcomes, what the compound did in the body, not pharmacokinetics; they belong to this page only as what the same trials also measured.

What does pharmacokinetics actually measure?

Pharmacokinetics is the study of what the body does to a compound over time — how fast it arrives in the blood, how high it climbs, how widely it spreads, and how long it takes to leave. Four measured quantities carry most of the answer: Cmax, the highest concentration reached; Tmax, how long it took to get there; t½, the half-life; and AUC, total exposure, the area under the whole concentration-versus-time curve. Retatrutide's numbers come from two trials: NCT03841630, a single-dose study in 45 dosed healthy adults in Singapore (Coskun et al., Cell Metabolism, 2022), and NCT04143802, a multiple-dose study in people with type 2 diabetes (Urva et al., The Lancet, 2022).

Pharmacokinetics has a mirror discipline, and the reader will meet the distinction again: pharmacokinetics is what the body does to the compound, while pharmacodynamics is what the compound does in the body. The gastric-emptying study on retatrutide's record is the clean example — it measured how fast the stomach emptied using paracetamol absorption, finding the paracetamol Tmax delayed by about an hour at Day 2 in the higher-dose groups, the effect largest after the first dose and diminished by Days 30 and 79, with total paracetamol exposure unaffected (Urva et al., Diabetes, Obesity and Metabolism, 2023). That is a pharmacodynamic reading. It adds no pharmacokinetic number for retatrutide itself.

The two trials behind every figure on this page ran from March to July 2019 in Singapore and from December 2019 to December 2020 in the United States — how long retatrutide has been studied lays out that full timeline, and where these two early studies sit inside it.

How long does retatrutide take to reach peak levels in the blood?

The highest blood concentration of retatrutide was observed between 12 and 72 hours after a single dose (Coskun et al., Cell Metabolism, 2022). In the single-dose trial, median times to peak fell as the dose rose, from 72 hours at the lowest single-dose level down to 12 hours at the next-to-highest level, with wide individual spreads at every level. A compound that takes one to three days to crest is behaving on a different clock from anything the body clears by evening.

The medians hide wide spreads. At the lowest dose level the median time to peak was 72.0 hours, with individuals out to 119.8 hours; at the next-to-highest level the earliest individual peak came at 4 hours against a median of 12.0 (Coskun et al., Cell Metabolism, 2022). The comparison table below carries the full dose-by-dose record. The paper reports the downward trend in peak timing as the dose rises and does not explain it, and neither does this page.

Does retatrutide exposure rise in step with the dose?

Retatrutide exposure rises close to in step with the dose. The single-dose trial reported that retatrutide's pharmacokinetics appeared nearly dose-proportional across the Coskun 2022 dose ladder — double the dose, roughly double the total exposure (Coskun et al., Cell Metabolism, 2022). The multiple-dose trial in people with type 2 diabetes reported dose-proportional pharmacokinetics as well (Urva et al., The Lancet, 2022). Proportionality matters because it makes levels predictable: what a trial measured at one dose level says something useful about the next.

Predictable on average is not identical person to person. Coefficients of variation — the spread around the mean, expressed as a percentage — ran from 13% to 34% for total exposure and from 10% to 37% for peak concentration in the single-dose trial (Coskun et al., Cell Metabolism, 2022). The same dose level produced meaningfully different exposures in different people. That spread is ordinary for peptides, and it is the reason a mean is a poor description of any one participant.

Why does retatrutide stay in the blood for days?

Retatrutide stays in the blood for days because the molecule is built for it. Retatrutide is a 39-amino-acid peptide on a GIP backbone with a C20 fatty diacid attached through a linker at Lys17, and that fatty-acid tail is the standard design for binding albumin, the carrier protein that makes up most of the protein in human blood (Coskun et al., Cell Metabolism, 2022). The paper also lists three engineered substitutions — Aib2, αMeL13, and Aib20 — that make the peptide harder for the body to break down.

Your albumin has been running a taxi service since long before anyone designed a peptide to hitch a ride. Fatty acids hop on, ride the circulation, and hop off where they are needed. A fatty-acid tail lets a peptide buy a ticket on the same service, and a molecule riding albumin is largely shielded from the fast clearance routes that sweep smaller, unattached compounds away — which is how a peptide that would otherwise clear in hours can linger for days.

One honest limit sits underneath the story. Albumin binding is the stated design rationale for the fatty-acid tail. The extracted single-dose text does not tabulate a human free fraction — the share of the compound travelling unbound — or a percentage bound, so this page does not supply one.

Is research-use retatrutide the same material the trials measured?

No. Every pharmacokinetic number on this page was measured on the trial drug product, administered to enrolled participants under clinical trial conditions (Coskun et al., Cell Metabolism, 2022; Urva et al., The Lancet, 2022). Research-use reference material is a laboratory compound. Retatrutide's published pharmacokinetics therefore describe one specific investigational product studied in two Phase 1 trials. Research material is not a medicine, is not a substitute for one, and is not for human or animal use. The trial measurements describe what happened inside those trials; they say nothing about any material outside them.

What exists for laboratory work is reference material with paperwork. Form Laboratories lists retatrutide reference material as freeze-dried laboratory stock with lot-matched documentation — a certificate of analysis tied to a specific batch. Reading that paperwork is its own skill — what a certificate records, what a third-party report proves, how a batch stays traceable — and the quality and verification hub walks through it. Retatrutide remains in Phase 3 trials and is approved in no country as of 2026.